- Stocks
- Healthcare
- NASDAQ: INCY

Price (delayed)

$64.34

Market cap

$14.45B

P/E Ratio

19.32

Dividend/share

N/A

EPS

$3.33

Enterprise value

$11.13B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,

INCY's net income has soared by 130% year-on-year and by 25% since the previous quarter

INCY's EPS has soared by 128% YoY and by 25% QoQ

The company's quick ratio fell by 12% YoY and by 7% QoQ

What are the main financial stats of INCY

Market
Valuations
Earnings

Shares outstanding

224.54M

Market cap

$14.45B

Enterprise value

$11.13B

Price to earnings (P/E)

19.32

Price to book (P/B)

2.68

Price to sales (P/S)

3.83

EV/EBIT

10.9

EV/EBITDA

10.06

EV/Sales

2.95

Revenue

$3.77B

EBIT

$1.02B

EBITDA

$1.11B

Free cash flow

$790.77M

Per share
Balance sheet
Liquidity

EPS

$3.33

Free cash flow per share

$3.52

Book value per share

$24.03

Revenue per share

$16.78

TBVPS

$30.57

Total assets

$7.14B

Total liabilities

$1.74B

Debt

$32.61M

Equity

$5.39B

Working capital

$3.45B

Debt to equity

0.01

Current ratio

3.47

Quick ratio

3.29

Net debt/EBITDA

-3

Margins
Efficiency
Dividend

EBITDA margin

29.4%

Gross margin

93.1%

Net margin

19.8%

Operating margin

18.3%

Return on assets

11.2%

Return on equity

14.7%

Return on invested capital

53%

Return on capital employed

17.8%

Return on sales

27.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Incyte stock price performed over time

Intraday

0.53%

1 week

5.94%

1 month

2.63%

1 year

5.34%

YTD

2.47%

QTD

6.14%

How have Incyte's revenue and profit performed over time

Revenue

$3.77B

Gross profit

$3.51B

Operating income

$687.65M

Net income

$745.44M

Gross margin

93.1%

Net margin

19.8%

INCY's net income has soared by 130% year-on-year and by 25% since the previous quarter

The net margin has soared by 113% year-on-year and by 22% since the previous quarter

Incyte's operating income has increased by 41% YoY and by 11% from the previous quarter

INCY's operating margin is up by 30% year-on-year and by 9% since the previous quarter

What is Incyte's growth rate over time

What is Incyte stock price valuation

P/E

19.32

P/B

2.68

P/S

3.83

EV/EBIT

10.9

EV/EBITDA

10.06

EV/Sales

2.95

INCY's EPS has soared by 128% YoY and by 25% QoQ

INCY's P/E is 30% below its last 4 quarters average of 27.3

The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 5.2

INCY's equity is up by 21% year-on-year and by 3.9% since the previous quarter

INCY's P/S is 35% below its 5-year quarterly average of 5.9 but 3% above its last 4 quarters average of 3.7

Incyte's revenue has increased by 9% YoY

How efficient is Incyte business performance

The ROE has soared by 93% YoY and by 19% from the previous quarter

INCY's return on assets has surged by 93% year-on-year and by 18% since the previous quarter

INCY's ROS has soared by 83% YoY and by 20% QoQ

The ROIC has soared by 66% YoY and by 15% from the previous quarter

What is INCY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INCY.

How did Incyte financials performed over time

INCY's total liabilities is up by 30% year-on-year and by 9% since the previous quarter

Incyte's total assets has increased by 23% YoY and by 5% from the previous quarter

The debt is 99% smaller than the equity

INCY's equity is up by 21% year-on-year and by 3.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.